LumiraDx to Sell its Cutting Edge Point of Care Technology Platform to Roche
Press releases | January 2, 2024
Fried Frank acted as counsel to LumiraDx Group Limited and LumiraDx International Limited (“LumiraDx”) and FTI Consulting LLP on the sale of its point-of-care diagnostics business to Roche Diagnostics Limited (“Roche”) for a headline purchase price of $295m. The sale was effected by way of a pre-packaged administration with Andrew Johnson, Lisa Rickelton and Lindsay Hallam of FTI Consulting appointed as administrators of the two companies. The transaction was structured as a sale of shares in a number of LumiraDx subsidiary companies and the assignment of certain intellectual property rights, which together comprise the LumiraDx “Platform ”diagnostics business (and the majority of the business and assets of the LumiraDx group).
The transaction is expected to close (subject to the satisfaction of certain conditions, including certain antitrust and FDI clearances) by 30 June 2024. Between signing and closing the LumiraDx business’ working capital requirements will be funded by up to $59 million of additional debt financing from LumiraDx’s existing senior lender (being funds affiliated to Pharmakon Advisors, LP). Subject to certain terms and conditions, up to $55m of this will be reimbursed by Roche upon completion under the terms and conditions of the sale and purchase agreement. The Nasdaq-listed LumiraDx group is a long-standing client of the Firm and following signing it is anticipated that the company will be delisted from Nasdaq and subject to winding up proceedings in the Cayman Islands.
The Fried Frank team was led by corporate partner Ian Lopez and Mandip Englund led the advice to the administrators.
This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.